Rheumatoid Arthritis

A Boston-based biopharma company announced the first participants have been dosed in its phase 1 study to assess safety, tolerability and pharmacokinetics of a novel oral, small molecule therapeutic in healthy adults.

Key details expressing arthralgia duration, morning stiffness or joint examination findings are often missing from rheumatology referral letters for inflammatory arthritis, according to data published in Rheumatology Advances in Practice.

Little evidence suggests that any specific biologic or targeted synthetic disease-modifying antirheumatic drug is superior to another for rheumatoid arthritis, highlighting the importance of individualized treatment, according to data.

I heard my first lecture about personalized or precision medicine in the early 1980s.

Patients across health care specialties have in recent years come to expect some form of individually tailored care — or precision medicine — as part of their disease management.

For patients with diseases such as lupus or rheumatoid arthritis who take low-dose drugs at lower frequencies, the relief afforded by over-the-counter drugs such as ibuprofen and naproxen can be a boon.

In patients with rheumatoid arthritis, NSAIDs and opioids demonstrate similar risks for major adverse cardiovascular events, while opioids exhibit higher rates of all-cause mortality and venous thromboembolism, according to data.

Patients receiving tofacitinib for rheumatoid arthritis with higher paraoxonase activity over time demonstrate a lower risk for major adverse cardiovascular events and malignancy, according to data published in the Journal of Rheumatology.

The FDA has approved Abrilada as the second interchangeable biosimilar to adalimumab, according to a press release from Pfizer.